Endpoints News

Drugmaker reports 4Q earnings, takes charge on cancer pipeline		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

3 February, 2026

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

presented by

Biggest SCOPE Buzz: Two Disruptors in Clinical Research Are Redefining Enrollment Speed

news

Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months

•

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings

AstraZeneca gets CRL for self-injectable pen version of lupus drug Saphnelo

Exclusive: Stanford duo joins AI scientist race with startup backed by a16z and Menlo

Analyst – Life Sciences Strategy & Intelligence

Sedulo Group

Remote

Vice President, Investor Relations & Communications

C4 Therapeutics

Watertown, MA, USA

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

endpoints pharma

Novo Nordisk’s CagriSema bests semaglutide in type 2 diabetes study

First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?

FDA opens submissions for PreCheck program to speed up US factory builds

FDA rejects Aquestive's allergy drug over packaging issues

Pharming’s immunodeficiency drug gets CRL for use in younger patients

in case you missed it

GSK gives back rights to Wave Life Sciences' lead RNA editing program

SanegeneBio licenses RNAi candidate to Genentech for $200M upfront

News Briefing

Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT

European law changes mean drugmakers may have to grapple with generic competition sooner

Sanofi’s rare disease drug notches one win, one loss in a pair of Phase 3 trials

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Senior FDA Official Under OIG Investigation Over Divorce, Assets

All eyes will be on Pfizer today, with the company sharing data from one of the obesity drugs it got from Metsera. It's also reporting its full-year earnings, revealing impairment losses of $4.4 billion and some pipeline cuts. Stay tuned.